VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,710,453 | +6.3% | 896,635 | +4.1% | 0.01% | +12.5% |
| Q2 2023 | $42,995,393 | +71.7% | 860,941 | +28.8% | 0.01% | +60.0% |
| Q1 2023 | $25,047,959 | -20.8% | 668,302 | +1.4% | 0.01% | -28.6% |
| Q4 2022 | $31,614,921 | +172.2% | 659,331 | +36.3% | 0.01% | +133.3% |
| Q3 2022 | $11,613,000 | +14.9% | 483,892 | +4.2% | 0.00% | +50.0% |
| Q2 2022 | $10,104,000 | +9.5% | 464,337 | +21.5% | 0.00% | 0.0% |
| Q1 2022 | $9,228,000 | +4.4% | 382,125 | +2.9% | 0.00% | +100.0% |
| Q4 2021 | $8,838,000 | -7.1% | 371,462 | -1.0% | 0.00% | -50.0% |
| Q3 2021 | $9,517,000 | +15.6% | 375,107 | +2.6% | 0.00% | +100.0% |
| Q2 2021 | $8,230,000 | +43.2% | 365,652 | +25.7% | 0.00% | 0.0% |
| Q1 2021 | $5,746,000 | -3.1% | 290,958 | +30.4% | 0.00% | 0.0% |
| Q4 2020 | $5,929,000 | -44.0% | 223,120 | +4.0% | 0.00% | -50.0% |
| Q3 2020 | $10,593,000 | – | 214,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,457,300 | $54,619,604 | 23.40% |
| Pivotal bioVenture Partners Investment Advisor LLC | 693,039 | $25,975,102 | 10.70% |
| RA Capital Management | 7,291,254 | $273,276,200 | 6.19% |
| Kynam Capital Management, LP | 1,216,784 | $45,605,064 | 5.89% |
| GREAT POINT PARTNERS LLC | 659,211 | $24,707,228 | 4.85% |
| Frazier Life Sciences Management, L.P. | 1,397,405 | $52,374,739 | 3.79% |
| ACUTA CAPITAL PARTNERS, LLC | 120,500 | $4,516,340 | 3.33% |
| Ghost Tree Capital, LLC | 225,000 | $8,433,000 | 2.49% |
| Carlyle Group Inc. | 1,923,158 | $72,079,962 | 2.15% |
| Opaleye Management Inc. | 177,000 | $6,633,960 | 1.99% |